Extensive Stage Small Cell Lung Cancer
4 competing products in clinical development for Extensive Stage Small Cell Lung Cancer.
Pipeline by Phase
Phase 12
Phase 1/21
Phase 21
All Products (4)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ifinatamab Deruxtecan (I-DXd) | Daiichi Sankyo | Phase 2 | Active | 39 |
| Ifinatamab deruxtecan + Atezolizumab + Carboplatin | Daiichi Sankyo | Phase 1/2 | Recruiting | 39 |
| ALPS12 + obinutuzumab | Chugai Pharmaceutical | Phase 1 | Recruiting | 36 |
| Valemetostat + Atezolizumab | Daiichi Sankyo | Phase 1 | Recruiting | 36 |